No benefit for TS-1/irinotecan combo in second-line gastric cancer
This article was originally published in Scrip
Executive Summary
Adding Taiho Pharmaceutical's TS-1 to irinotecan for the second-line treatment of gastric cancer patients refractory to first-line TS-1 therapy confers no survival benefit over irinotecan alone, new summary results from a Japanese Phase III trial show.